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Background: The prevalence of chronic obstructive pulmonary disease (COPD) in Abu Dhabi,
United Arab Emirates is unknown.
Methods: We conducted a cross-sectional survey in a random sample of individuals 40e80 years
old in Abu Dhabi, with a particular interest to explore local risk factors other than cigarette
smoking. Airflow limitation compatible with COPD was defined as a post-bronchodilator ratio
FEV1/FVC <0.70.
Results: From 520 participants surveyed (93.7% response rate), 55% male and with a mean age
of 52 years, the prevalence of COPD was 3.7% and 95% C.I. (2.0e5.3). There were no differ-
ences by gender, and COPD prevalence only significantly increased in those 70 year and older.
Among those with COPD, cigarette smoking use was relatively low (12% current- and 12%
former-smokers), and it was even lower the use of shisha (5%), pipe (0%), or exposure to
passive smoking (5%), while exposure to biomass was higher (33%). Interestingly, bakhour
use was very high (78%), but neither bakhour nor any of the above-mentioned exposures were
associated with the risk of COPD.
Conclusions: COPD prevalence in 40e80 years old in Abu Dhabi was 3.7%, and associations with
cigarette smoking or with other local inhaled exposures were not observed.
Crown Copyright ª 2010 Published by Elsevier Ltd. All rights reserved.Epidemiology and Clinical Research, Fundacio´ Caubet-CIMERA Illes Balears, Recinte Hospital Joan
Bunyola, Spain. Tel.: þ34 971 14 84 37; fax: þ34 971 14 84 42.
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Overall, the prevalence of COPD in the general population is
estimated to bew1% across all ages, rising steeply to 8e10%
or higher amongst those aged 40 years.1 However, there
remain many large regions in the World with no actual data
contributing to these estimates.2 There are no data on the
extent of COPD in Abu Dhabi or in the United Arab Emirates
(UAE).Bymeansofpost-bronchodilator spirometry,weaimed
to determine the prevalence of COPD and to explore local risk
factors other than cigarette smoking, namely passive
smoking, bakhour, shisha, pipe, and biomass exposures.Material and methods
We conducted a cross-sectional survey in the catchment
population of the Zayed Military Hospital in Abu Dhabi. Male
and female individuals, aged 40e80 years old, residents in
the UAE were recruited sequentially by random phone callsFigure 1 CONSORT flowat home, and offered to participate in this study irrespective
of their respiratory history or smoking. Fieldwork was con-
ducted from May 2009 to May 2010. This research protocol
was approved by our Clinical Research Ethics Authority, and
all participants signed an informed written consent.
Our questionnaire was based on the original ATS ques-
tionnaire.3 In addition to standard questions on active and
passive smoking, other items were included to assess the
local factors, namely biomass, bakhour (also called Arabian
incense), and shisha.
Spirometry was conducted according to ATS/ERS stan-
dards,4 by means of spirometers VIASYS JAEGER FlowScreen
V2.5 (Hoechberg, Germany). Reference values were those of
NHANES-III.5 Reported values correspond to those determined
after inhalation of 200 mcg of salbutamol. AL compatible with
COPD was defined according to the GOLD guidelines as a post-
bronchodilator FEV1/FVC<0.7.
6 The severity of ALwas staged
according also to the GOLD guidelines as mild, moderate,
severe and very severe if percent predicted FEV1 was >80%,
50e80%, 30e50%, or <30%, respectively.6-chart of participants.
Table 1 Demographic characteristics of participants.
Variable COPD (n Z 19) Normal lung function (n Z 501) P value
Male gender, n (%) 11 (58%) 275 (55%) 0.796
Age in years, mean (SD) 56.8 (9.9) 51.7 (7.9) [40e80] 0.006
Nationality, n (%) 0.946
UAE 12 (63%) 375 (75%)
European 0 (0%) 11 (2%)
Other 7 (37%) 115 (23%)
Emirate, n (%) 0.777
Abu Dhabi 17 (89%) 379 (77%)
Other 2 (11%) 122 (23%)
Education, n (%) 0.836
None 8 (42%) 139 (28%)
Primary 4 (21%) 129 (26%)
Secondary 4 (21%) 130 (26%)
University 3 (16%) 96 (19%)
Marital status, n (%) 0.978
Married 16 (84%) 427 (85%)
Other 3 (16%) 74 (15%)
BMI, mean (SD) 30.7 (5.7) 31.2 (6.0) 0.742
Data are presented as mean and standard deviation (SD) for continuous variables, or percentage for qualitative variables, as appro-
priate. Differences within groups were compared with analysis of variance (ANOVA) for continuous variables, and Chi2 for categorical
variables.
568 A. Al Zaabi et al.The prevalence of AL compatible with COPD and its 95%
confidence intervalswas estimated for all participants, andby
gender and age bands. The risk of COPDby covariates (namely
male gender, age in years) and exposures (namely smoking
ever, bakhour user, shisha use, pipe smoking use, and biomass
exposure) was explored in bivariate analyses, as well as all
variables adjusted in a logistic regression analysis. A p value
lower than 0.05 was considered statistically significant.
Results
From the catchment population of the ZayedMilitaryHospital
in Abu Dhabi, the sample of 900 subjects with ages 40e80
years was selected. Then, the first 555 in a randomly gener-
ated listwere invitedtoparticipate,andfinally520conducted
spirometry. Reasons for non-response were: 30 (5.4%) phone






























Figure 2 Prevalence of COPD (and 9participate for either no reason, being sick or too old (Fig. 1).
With a 93.7% response rate, the final sample of 520 partici-
pants surveyed was made of 55% male, with a mean age of 52
years, of mainly UAE nationals, most of them born in Abu
Dhabi (Table 1). Thosewith COPDwere older (p< 0.05),more
frequently non-UAE Nationals, andwith lower education than
thosewithnormal lung function (p> 0.05). The corresponding
prevalence of COPD was 3.7% and 95% C.I. (2.0e5.3). Inter-
estingly, there were no differences by gender, male 3.8% vs
95%C.I. (1.6e6.1)and female3.4%and95%C.I. (1.1e5.7); and
COPD prevalence only significantly increased in those 70 and
older, 20.0% (0.1e40.2) (Fig. 2).
These COPD patients were rarely previously diagnosed of
COPD (5.3%) or received respiratory treatment (10.5),
although nearly half reported having asthma. The GOLD
severity distribution was 5.3% mild, 63.2% moderate, 31.6%
severe, and 0 (0%) very severe (Table 2).40-49 yrs 50-59 yrs 60-69 yrs 70-80 yrs
5% C.I.) by gender and age bands.
Table 2 Clinical characteristics of participants.
Variable COPD (n Z 19) Normal lung function (n Z 501) P value
Symptoms, n (%)
Wheezing 9 (47.4%) 35 (7.0) <0.001
Cough 9 (47.4%) 38 (7.6%) <0.001
Sputum 9 (47.4%) 54 (10.8%) <0.001
Dyspnea 8 (42.1%) 40 (8.0%) <0.001
Previous Dx, n (%)
COPD 1 (5.3%) 3 (0.6%) <0.001
Asthma 9 (47.4%) 23 (4.6%) <0.001
Receiving respiratory treatment, n (%) 2 (10.5%) 3 (0.6%) <0.001
Family history of COPD, n (%) 2 (10.5%) 5 (1.0%) <0.001
FEV1/FVC preBD, mean (SD) 63.1 (7.1) 82.7 (6.4) <0.001
FEV1/FVC postBD, mean (SD) 62.7 (5.0) 79.5 (6.2) <0.001
Severity of airflow limitation, n (%)
Mild 1 (5.3%) e e
Moderate 12 (63.2%)
Severe 6 (31.6%)
Very severe 0 (0%)
Smoking status, n (%) 0.884
Active 2 (12%) 60 (13%)
Ex-smoker 2 (12%) 80 (17%)
Never-smoker 12 (75%) 328 (70%)
Pack-years, mean (SD) 18.4 (15.4) 22.6 (23.2) 0.720
Passive smoking, n (%) 1 (5.3%) 129 (25.7%) 0.055
Bakhour use, n (%) 0.757
Never 4 (22%) 81 (19%)
User 14 (78%) 353 (81%)
Once/week 3 (17%) 125 (19%)
Twice/week 5 (28%) 88 (20%)
Three or more/week 6 (33%) 140 (32%)
Shisha use, n (%) 0.715
Current 1 (5%) 24 (5%)
Ex-shisha smoker 0 (0%) 17 (3%)
Never-smoker 18 (95%) 460 (92%)
Heads of shisha/day, mean (SD) 0.5 (1) 2.0 (2.0) 0.002
Years of shisha, mean (SD) [range] 10.0 (1) 8.9 (8.8) 0.856
Pipe smoking use, n (%) 0.792
Current 0 (0%) 10 (2%)
Ex-smoker 0 (0%) 2 (0%)
Never-smoker 19 (100%) 489 (98%)
Pipes/day, mean (SD) e 9.8 (8.9) e
Biomass exposure, n (%) 0.039
Never 6 (67%) 195 (84%)
Ever 3 (33%) 38 (16%)
Once/week 0 (0%) 19 (8%)
Twice/week 2 (22%) 9 (4%)
Three or more/week 1 (11%) 10 (4%)
Prevalence of COPD in the UAE 569Among those with COPD, cigarette smoking use was rela-
tively low, and it was even lower the use of shisha, pipe, or
exposure to passive smoking, while exposure to biomass was
higher. Interestingly, bakhour use was very high (78%), but
neither bakhour nor any of the above-mentioned exposures
were associated with the risk of COPD. The final multivariate
analysis for AL compatible with COPD produced the following
adjustedodds ratios and95%confidence intervals:Male gender
1.75 (0.54e5.64); Age in years 1.10 (1.03e1.16); Smoking ever
0.52 (0.13e2.10); and Bakhour user 0.50 (0.14e1.75). Apart
from age, all of them were non-statistically significant.Discussion
Ours is the first prevalence survey with post-bronchodi-
lator spirometry conducted in Abu Dhabi and in the UAE
to date.
Advantages of our study include a decent sample size,
and a high participation rate. Among the limitations, the
representativity of our source population to the general
population of Abu Dhabi, UAE deserves further discussion.
In 2009, the UAE population was estimated at 6 million,
570 A. Al Zaabi et al.under 20% being Emiratis, the male/female ratio was higher
than two, and 25.5% of males and 1.6% of females smoke.7
We suggest our results are indirect evidence that COPD
prevalence is low in UAE nationals, but the statistical power
to detect modest associations with risk factors was prob-
ably small, in view of the small number of patients with
COPD identified in our survey.
There is scarce data in the literature on respiratory
conditions in the region. A small, old case-control study in
Saudi Arabia found no association with COPD and the use of
incense burners.8 Al-Rawas et al., reported that bakhour
burning is a common trigger of wheezing among asthmatic
children in Oman, but it was not associated with asthma
prevalence.9 The harm ofwaterpipe tobacco smoking on lung
function has been estimated, concluding it is likely to cause
COPD.10
When compared with other international, published
data,11,12 our estimate positions the UAE amongst the lower
prevalences of COPD.
We conclude that COPD in those 40e80 years old in Abu
Dhabi, UAE is low (3.7%). The observed low COPD prevalence
and the absence of associations with cigarette smoking or
with other local inhaled exposures, deserve further
investigation.
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